ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Ascendis Pharma A/S

Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Feb 11, 2026

$229.95+4.70 (+2.09%)

Close on Oct 19, 2026

Community

Notes and questions about Ascendis Pharma A/S from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Ascendis Pharma A/S's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ASND.

Revenue growth98.0% · median 36.3%

Gross margin86.8% · median 96.4%

Operating margin-18.9% · median 0.8%

Net margin-31.7% · median -4.5%

Advertisement
300 × 250